Modular PROTAC Design for the Degradation of Oncogenic BCR‐ABL |
| |
| Authors: | Ashton C. Lai Dr. Momar Toure Dr. Doris Hellerschmied Jemilat Salami Dr. Saul Jaime‐Figueroa Dr. Eunhwa Ko Dr. John Hines Prof. Craig M. Crews |
| |
| Affiliation: | 1. Departments of Chemistry;2. Molecular, Cellular & Developmental Biology;3. Pharmacology, Yale University, New Haven, CT 06511 (USA) |
| |
| Abstract: | Proteolysis Targeting Chimera (PROTAC) technology is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs. PROTAC technology employs small molecules that recruit target proteins for ubiquitination and removal by the proteasome. The synthesis of PROTAC compounds that mediate the degradation of c‐ABL and BCR‐ABL by recruiting either Cereblon or Von Hippel Lindau E3 ligases is reported. During the course of their development, we discovered that the capacity of a PROTAC to induce degradation involves more than just target binding: the identity of the inhibitor warhead and the recruited E3 ligase largely determine the degradation profiles of the compounds; thus, as a starting point for PROTAC development, both the target ligand and the recruited E3 ligase should be varied to rapidly generate a PROTAC with the desired degradation profile. |
| |
| Keywords: | cancer drug design E3 ubiquitin ligases inhibitors protein degradation |
|
